June 8, 2005
AnGes MG, Inc.

AnGes MG Starts to Explore Feasibility of a New DDS Drug with MedGel
- Toward Expanding the Application Range of NFκB Decoy Oligo -

AnGes MG, Inc. and MedGel CORPORATION have begun a feasibility study on a new drug for inflammatory diseases that is a combination of NFκB decoy oligodeoxynucleotide (NFκB decoy oligo), which is a nucleic acid medicine developed by AnGes MG, and a new material developed by MedGel.

AnGes MG has been developing NFκB decoy oligo,as a topical skin product for atopic dermatitis as an indication for cutaneous diseases. In parallel with this development, AnGes MG has already performed a drug study for further enhancement of the therapeutic effects of NFκB decoy oligo. At this time, a feasibility study will be commenced for a drug delivery material developed by MedGel.

Founded in April 2003 with research achievements of Professor Yasuhiko Tabata at the Institute for Frontier Medical Sciences in Kyoto University, MedGel deals with a wide range of drugs including protein medicines and nucleic acid medicines, and develops materials that amplify their effects. Moving into the Saito Bio Incubator in Osaka Prefecture this May, MedGel is working to accelerate completion of the feasibility study being produced in collaboration with AnGes MG.

In the present feasibility study, AnGes MG will investigate expansion of the application range of NFκB decoy oligo in combination with the amplifying material supplied by MedGel.

Company Profile
MedGel CORPORATION
Headquarters : 668-3 Motozaimoku-cho, Fushimi-ku, Kyoto City, Kyoto
President : Tomohiko Asahara
Establishment : 2003
Capital: 40,000,000 yen (as of April, 2005)
Business Contents : Development of new materials which add functional value to drugs